Submissions

The following are publicly available submissions to public consultations made by Asthma Australia since its formation as a national body in 2018. 

Pharmaceutical Benefits Advisory Council

Asthma Australia has made submissions to PBAC regarding the following medicines:

  • 2022

    Dupixent  

    Fostair 200 

    Tezspire

    Trimbow  

  • 2021

    Trelegy 

    Xolair

  • 2020

    Atectura 

    Dupixent  

    Enerzair 

    Fostair 

    Spiriva Respimat 

  • 2019

    Budesonide with Formoterol  

    Fluticasone Furoate  

    Salbutamol 

    Symbicort 

  • 2018

    Benralizumab 

    Tiotropium 

Therapeutic Goods Administration

Asthma Australia has made submissions to the TGA regarding the following consultations  

  • 2022

    Down scheduling inhaled budesonide 

  • 2021

    Standard for vaporiser nicotine (TGO 110)  

  • 2020

    Interim decision to amend the Poisons Standard (nicotine) 

  • 2019

    Increased online access to ingredient information 

  • 2018

    Management and communication of medicines shortages